Plus Therapeutics Inc (PSTV)

$0.51 -0.01 (-2.41%)
Market Cap 76.55M
Revenue (ttm) 5.82M
Net Income (ttm) -12.98M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 1.27
Profit Margin -223.02%
Debt to Equity Ratio 0.00
Volume 2,333,710
Avg Vol 22,235,686
Day's Range N/A - N/A
Shares Out 137.43M
Stochastic %K 35%
Beta 0.77
Analysts Strong Sell
Price Target $7.75

Company Profile

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is REYOBIQ, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid...

Industry: Biotechnology
Sector: Healthcare
Phone: 737 255 7194
Fax: 210 974 6901
Address:
2710 Reed Road, Suite 160, Houston, United States
Cheffinance
Cheffinance Nov. 14 at 9:02 PM
$PSTV very disappointed close, week with volumes very low. They need to annunce 180 days and other PR otherwise this will sleep on 0,50usd. Love your stakeholders...nice weekend my friends🐳🚀🏝
0 · Reply
Love_To_Learn
Love_To_Learn Nov. 14 at 8:25 PM
$PSTV MODIFYING 1.411 BILLION SHARES INTO THE VAULT
0 · Reply
Love_To_Learn
Love_To_Learn Nov. 14 at 8:04 PM
$PSTV TRANSFERRING OUT 550 MILLION SHARES OFF THE BOOKS
0 · Reply
Cheffinance
Cheffinance Nov. 14 at 7:28 PM
$PSTV i'm very curious to see how it this last hour 🐳🚀🏝
1 · Reply
flywithfitz81
flywithfitz81 Nov. 14 at 7:14 PM
$OSTX $PSTV $CNC $FI Rather than a blah day... maybe let's add a little salt n' pepper. It is Friday after all.
0 · Reply
Tvsect
Tvsect Nov. 14 at 5:23 PM
$PSTV added
1 · Reply
bambus3001
bambus3001 Nov. 14 at 5:08 PM
$PSTV Eine Perle die eine goldene Zeit vor sich haben könnte ,enormes Potential was UNH schon erkannt hat.
0 · Reply
dubrockin
dubrockin Nov. 14 at 4:29 PM
$PSTV is a fine harbor in bad weather.
0 · Reply
Lake_Life24
Lake_Life24 Nov. 14 at 4:17 PM
$PSTV This company has so much potential to heal people and make a shit load of money doing it! Holding
0 · Reply
flywithfitz81
flywithfitz81 Nov. 14 at 4:15 PM
$PSTV What is this guy still doing here? No one is interested in your pretend dilution or fake revenue insight. You don't know more than your ass from your elbow. That is apparent, if shorts had any chance, it was today. Good luck, hope you cover. I don't want to see you hurt.
0 · Reply
Latest News on PSTV
Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.0

Nov 6, 2025, 7:30 AM EST - 8 days ago

Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.0

Plus Therapeutics Reports Third Quarter Financial Results and Recent Business Highlights

Oct 30, 2025, 4:15 PM EDT - 15 days ago

Plus Therapeutics Reports Third Quarter Financial Results and Recent Business Highlights

Plus Therapeutics Updates on CNSide® Diagnostic Platform Launch

Oct 21, 2025, 7:30 AM EDT - 24 days ago

Plus Therapeutics Updates on CNSide® Diagnostic Platform Launch

Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Sep 25, 2025, 7:30 AM EDT - 7 weeks ago

Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Plus Therapeutics Announces Additional $1.9 Million Advance Payment from CPRIT

Sep 22, 2025, 7:30 AM EDT - 7 weeks ago

Plus Therapeutics Announces Additional $1.9 Million Advance Payment from CPRIT

Plus Therapeutics Announces Successful Accreditation and Certification for Its CNSide® Diagnostics Clinical Laboratory

Sep 18, 2025, 7:30 AM EDT - 2 months ago

Plus Therapeutics Announces Successful Accreditation and Certification for Its CNSide® Diagnostics Clinical Laboratory

Plus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 4:15 PM EDT - 2 months ago

Plus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Plus Therapeutics Regains Compliance with Applicable Nasdaq Listing Criteria

Aug 26, 2025, 7:30 AM EDT - 2 months ago

Plus Therapeutics Regains Compliance with Applicable Nasdaq Listing Criteria

Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases

Aug 18, 2025, 7:30 AM EDT - 3 months ago

Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases

Plus Therapeutics Reports Stockholders' Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements

Aug 15, 2025, 7:30 AM EDT - 3 months ago

Plus Therapeutics Reports Stockholders' Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements

Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights

Aug 14, 2025, 4:15 PM EDT - 3 months ago

Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights

Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases Conference

Aug 14, 2025, 7:30 AM EDT - 3 months ago

Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases Conference

Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic

Jul 31, 2025, 7:30 AM EDT - 3 months ago

Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic

Plus Therapeutics Announces $1.6 Million Advance Payment from CPRIT

Jul 23, 2025, 7:30 AM EDT - 4 months ago

Plus Therapeutics Announces $1.6 Million Advance Payment from CPRIT

Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases

Jul 15, 2025, 7:30 AM EDT - 4 months ago

Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases

Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference

Jul 10, 2025, 7:30 AM EDT - 4 months ago

Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference

Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

Jul 8, 2025, 7:30 AM EDT - 4 months ago

Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

Jun 30, 2025, 7:30 AM EDT - 4 months ago

Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary

Jun 26, 2025, 7:30 AM EDT - 5 months ago

Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary

Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, June 26, 2025 at 9:00 A.M. ET

Jun 25, 2025, 4:15 PM EDT - 5 months ago

Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, June 26, 2025 at 9:00 A.M. ET

Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer

Jun 25, 2025, 7:30 AM EDT - 5 months ago

Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer

Plus Therapeutics Announces Comprehensive Restructuring of $15 Million March 2025 Equity Financing

Jun 24, 2025, 7:30 AM EDT - 5 months ago

Plus Therapeutics Announces Comprehensive Restructuring of $15 Million March 2025 Equity Financing

Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights

May 30, 2025, 4:15 PM EDT - 6 months ago

Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights

Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

May 23, 2025, 4:15 PM EDT - 6 months ago

Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

Plus Therapeutics' REYOBIQ™ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM)

May 14, 2025, 7:30 AM EDT - 6 months ago

Plus Therapeutics' REYOBIQ™ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM)

Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference

May 8, 2025, 7:00 AM EDT - 6 months ago

Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference

Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors

Apr 23, 2025, 8:00 AM EDT - 7 months ago

Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors

Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases

Apr 15, 2025, 7:30 AM EDT - 7 months ago

Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases

Plus Therapeutics, Inc. (PSTV) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 7:42 PM EDT - 8 months ago

Plus Therapeutics, Inc. (PSTV) Q4 2024 Earnings Call Transcript

Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Mar 27, 2025, 4:05 PM EDT - 8 months ago

Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate

Mar 20, 2025, 7:30 AM EDT - 8 months ago

Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate

Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025

Mar 19, 2025, 7:30 AM EDT - 8 months ago

Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025

D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement

Mar 11, 2025, 11:00 AM EDT - 8 months ago

D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement

Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement

Mar 10, 2025, 7:30 AM EDT - 8 months ago

Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement

Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma

Mar 7, 2025, 7:30 AM EST - 9 months ago

Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer

Mar 6, 2025, 7:30 AM EST - 9 months ago

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer

Plus Therapeutics Announces New Employment Inducement Grants

Mar 5, 2025, 4:01 PM EST - 9 months ago

Plus Therapeutics Announces New Employment Inducement Grants

Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds

Mar 4, 2025, 2:06 PM EST - 9 months ago

Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds

Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal Metastases

Feb 26, 2025, 7:30 AM EST - 9 months ago

Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal Metastases

Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary

Feb 24, 2025, 7:30 AM EST - 9 months ago

Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary

Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer

Feb 20, 2025, 7:30 AM EST - 9 months ago

Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer

Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program

Feb 18, 2025, 7:30 AM EST - 9 months ago

Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium

Dec 17, 2024, 7:30 AM EST - 11 months ago

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium

Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium

Dec 4, 2024, 7:30 AM EST - 1 year ago

Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium

Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply

Dec 3, 2024, 7:30 AM EST - 1 year ago

Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference

Nov 25, 2024, 7:30 AM EST - 1 year ago

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference

Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases

Nov 22, 2024, 7:30 AM EST - 1 year ago

Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases

Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases

Nov 21, 2024, 7:30 AM EST - 1 year ago

Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases

Plus Therapeutics, Inc. (PSTV) Q3 2024 Earnings Call Transcript

Nov 16, 2024, 2:45 PM EST - 1 year ago

Plus Therapeutics, Inc. (PSTV) Q3 2024 Earnings Call Transcript

Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 14, 2024, 4:15 PM EST - 1 year ago

Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Cheffinance
Cheffinance Nov. 14 at 9:02 PM
$PSTV very disappointed close, week with volumes very low. They need to annunce 180 days and other PR otherwise this will sleep on 0,50usd. Love your stakeholders...nice weekend my friends🐳🚀🏝
0 · Reply
Love_To_Learn
Love_To_Learn Nov. 14 at 8:25 PM
$PSTV MODIFYING 1.411 BILLION SHARES INTO THE VAULT
0 · Reply
Love_To_Learn
Love_To_Learn Nov. 14 at 8:04 PM
$PSTV TRANSFERRING OUT 550 MILLION SHARES OFF THE BOOKS
0 · Reply
Cheffinance
Cheffinance Nov. 14 at 7:28 PM
$PSTV i'm very curious to see how it this last hour 🐳🚀🏝
1 · Reply
flywithfitz81
flywithfitz81 Nov. 14 at 7:14 PM
$OSTX $PSTV $CNC $FI Rather than a blah day... maybe let's add a little salt n' pepper. It is Friday after all.
0 · Reply
Tvsect
Tvsect Nov. 14 at 5:23 PM
$PSTV added
1 · Reply
bambus3001
bambus3001 Nov. 14 at 5:08 PM
$PSTV Eine Perle die eine goldene Zeit vor sich haben könnte ,enormes Potential was UNH schon erkannt hat.
0 · Reply
dubrockin
dubrockin Nov. 14 at 4:29 PM
$PSTV is a fine harbor in bad weather.
0 · Reply
Lake_Life24
Lake_Life24 Nov. 14 at 4:17 PM
$PSTV This company has so much potential to heal people and make a shit load of money doing it! Holding
0 · Reply
flywithfitz81
flywithfitz81 Nov. 14 at 4:15 PM
$PSTV What is this guy still doing here? No one is interested in your pretend dilution or fake revenue insight. You don't know more than your ass from your elbow. That is apparent, if shorts had any chance, it was today. Good luck, hope you cover. I don't want to see you hurt.
0 · Reply
flywithfitz81
flywithfitz81 Nov. 14 at 4:14 PM
$PSTV Short interest is low and that has benefits. Days like today are one of them. While the market throws fits and looks to be starting to drop off it's peak, PSTV is holding it's support very well. That is institutional buying and confidence there. This ain't budging.
0 · Reply
alcat1973
alcat1973 Nov. 14 at 4:06 PM
$PSTV What is the status of having a RS. I read that they had until just a few days ago to meet the 1.00 per share requirement. Have they filed for an extension?
0 · Reply
Johnnyb1973
Johnnyb1973 Nov. 14 at 4:05 PM
$PSTV She's bottomed out!!!
0 · Reply
Redd_bull
Redd_bull Nov. 14 at 3:58 PM
$PSTV Patience is key. Good luck everyone
0 · Reply
Keywest20
Keywest20 Nov. 14 at 3:56 PM
$PSTV for fuck sake, your wieners gonna fall off unfortunately we’ve all been holding for a long time
0 · Reply
Samshar
Samshar Nov. 14 at 3:48 PM
$PSTV .60 soon
0 · Reply
Cheffinance
Cheffinance Nov. 14 at 3:45 PM
$PSTV my little bear diluition is normal for this kind of research small cap. I think ypu will in silence fir all his day and next week🤭🤭🤭🐳🚀🏝
0 · Reply
dang1976
dang1976 Nov. 14 at 3:40 PM
$PSTV, just holding !
0 · Reply
moneytra1n
moneytra1n Nov. 14 at 3:29 PM
$PSTV they are months behind on their full enrollment targets for p2 rGBM. If you spoke to IR once in a while you would know they wont be fully enrolled until late q1 2026 or early q2 2026. Still a long way to burn cash. 🔥
0 · Reply
Cheffinance
Cheffinance Nov. 14 at 3:25 PM
$PSTV take a look to linkedin page 🤭🤭🤭🐳🚀🏝
0 · Reply
RWGotrocks
RWGotrocks Nov. 14 at 3:15 PM
$PSTV Many here keep talking about $1. Just give us .70. This has been stuck in the mud for 2 weeks. .57 was highest in weeks. Where's the big news? Not sure how it will make $1. Just being realistic. I hope it starts ascending soon.
1 · Reply
moneytra1n
moneytra1n Nov. 14 at 3:15 PM
$PSTV $GCTK the cancer of ST trying to short cancer and blood therapeutic companies to the ground. Eventually they will lose but for now be warned for red on all tickers mentioned.
0 · Reply